Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HPP 737

Drug Profile

HPP 737

Alternative Names: HPP-737

Latest Information Update: 17 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator vTv Therapeutics LLC
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Dec 2019 Phase I development in Chronic obstructive pulmonary disease is ongoing in USA (vTv Therapeutics pipeline, December 2019)
  • 28 Feb 2019 No recent reports of development identified for phase-I development in Chronic obstructive pulmonary disease in USA
  • 31 May 2018 HPP 737 licensed to Newsoara Biopharma in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries, covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top